Back

Clinical characteristics and outcomes in a cohort of patients starting treatment with vericiguat in the US.

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy (2) Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Alexander Michel

Bayer AG, Basel (Switzerland)

5 More presentations in this session

Presentation thumbnail
Which treatment attributes do patients with transthyretin amyloid cardiomyopathy value most?
Ms A. Carr (Hagersville, CA)
Abstract Slides Video
Presentation thumbnail
Using dapagliflozin to reduce NT-proBNP and improve symptom in transthyretin cardiac amyloidosis - a series of n-of-1 trials pilot study
Doctor E. Haakansson (Umea, SE)
Abstract Slides Video
Presentation thumbnail
The care-gap for women living with heart failure
Doctor O. Graham (Craigavon, GB)
Abstract Slides Video
Presentation thumbnail
Intermittent levosimendan therapy and survival outcomes in advanced heart failure: insights from a real-world single-centre study
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Ambulatory blood pressure monitoring reveals true significant hypotension in stable HF patients; Is this an overlooked issue?
Doctor G. Bruno (Limerick, IE)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy (2)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Incidence of cardiovascular events following vericiguat initiation in patients with heart failure with or without a recent worsening heart failure event: a hospital-based real-world cohort study
thumbnail
Congress Presentation
Dose titration among patients receiving vericiguat in real-world clinical practice and association with clinical outcomes and health care resource use
thumbnail
Congress Presentation
Real-world treatment patterns in newly diagnosed heart failure patients stratified by ejection fraction subtype in Japan

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources